ZIM
VNDA icon

Zacks Investment Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Zacks Investment Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,471
Closed -$71K – 780
2025
Q1 		$71K Hold
15,471
– – ﹤0.01% 637
2024
Q4 		$74.1K Buy
+15,471
New +$74.3K ﹤0.01% 652
2019
Q1 		– Sell
-43,924
Closed -$1.15M – 602
2018
Q4 		$1.15M Sell
43,924
-29,627
-40% -$697K 0.03% 323
2018
Q3 		$1.69M Buy
+73,551
New +$1.5M 0.04% 312

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Zacks Investment Management's VNDA Position: Q2 2025 in Review

Zacks Investment Management sold out of Vanda Pharmaceuticals (VNDA) in Q2 2025, closing a stake of 15,471 shares — an estimated $71K sold.

Zacks Investment Management first reported a position in VNDA in Q3 2018 and held it in 4 quarters. The position peaked at $1.69M in Q3 2018. 139 funds tracked by Wall St. Rank hold VNDA as of Q2 2025.

  • Zacks Investment Management reported no remaining Vanda Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Zacks Investment Management sold 15,471 Vanda Pharmaceuticals shares in Q2 2025, an estimated $71K.
  • Zacks Investment Management first reported a position in Vanda Pharmaceuticals in Q3 2018 and held it in 4 quarters.
  • Zacks Investment Management's Vanda Pharmaceuticals position peaked at $1.69M in Q3 2018.
  • 139 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2025.

Based on Zacks Investment Management's 13F filing for Q2 2025, filed 12 Aug 2025.